Nanoparticles for use in enhancing brain performances or in treating stress
Inventors
Pottier, Agnès • Levy, Laurent • Meyre, Marie-Edith
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11471482-B2
Publication Date
2022-10-18
Expiration Date
Abstract
The present invention relates to the medical field, in particular to the enhancement of brain performances and for the treatment of pathological stress. More specifically the present invention relates to a nanoparticle or nanoparticles' aggregate for use in enhancing brain performances or in prevention or treatment of pathological stress in a subject without exposure of the nanoparticle or nanoparticles' aggregate to an electric field, and preferably without exposure thereof to any other external activation source, wherein the nanoparticle's or nanoparticles' aggregate's material is selected from a conductor material, a semiconductor material, an insulator material with a dielectric constant εijk equal to or above (200), and an insulator material with a dielectric constant εijk equal to or below (100). It further relates to compositions and kits comprising such nanoparticles and/or nanoparticles' aggregates as well as to uses thereof without exposure thereof to an electric field, and preferably without exposure thereof to any other external activation source such as a light source, a magnetic field, or an ultrasound source.
Core Innovation
A method enhances brain performance or prevents or treats pathological stress in a subject by administering a nanoparticle or nanoparticle aggregate, or a composition comprising nanoparticles and/or nanoparticle aggregates and a pharmaceutically acceptable support. The nanoparticles are selected from conductor materials, semiconductor materials, or insulator materials with defined dielectric or electronic constraints measured over a temperature range and a frequency range.
The conductor option requires a standard reduction potential E0 above 0.2 and/or an organic material having contiguous sp2 hybridized carbon centers in its structure, while the semiconductor option requires a band gap Eg below 3.0 eV. The insulator material is defined by dielectric constant εijk thresholds, including a mixed-metal oxide insulator material with εijk equal to or above 200 and an insulator material with εijk equal to or below 100 selected from named oxides and carbon diamond, with εijk measured between 20°C and 30°C and between 10^2 Hz up to the infrared frequency.
For the nanoparticle or nanoparticle aggregate population, the median largest core size of the core is at least 30 nm for the conductor, semiconductor, and for the insulator class with εijk equal to or above 200. The core is coated with a biocompatible coating that provides a neutral or a negative surface charge in water with electrolytes between 0.001 and 0.2 M, nanoparticle concentration between 0.01 and 10 g/L, and pH between 6 and 8.
The method excludes using the nanoparticle or nanoparticle aggregate as carrier of therapeutic compound(s) or drug(s), and it excludes any step of exposing the nanoparticle or nanoparticle aggregate to an electric field or any other external activation source. A composition or kit is also described that includes at least two distinct nanoparticles or nanoparticle aggregates with the same material classes and constraints, and with the exclusion that the nanoparticles or nanoparticle aggregates are not used as carrier of therapeutic compound(s) or drug(s).
Claims Coverage
The provided portion includes two independent claims. Both claims share core inventive constraints: specified conductor, semiconductor, and insulator material classes with defined dielectric or electronic property ranges, nanoparticle core-size and biocompatible coating that yields neutral or negative surface charge under aqueous electrolyte and pH conditions, and explicit exclusions regarding therapeutic-compound loading and external activation.
Administering nanoparticles to enhance brain performance or prevent or treat pathological stress without electric-field or external activation
A method for enhancing brain performance or for preventing or treating pathological stress in a subject by administering a nanoparticle or nanoparticle aggregate, or a composition comprising nanoparticles and/or nanoparticle aggregates and a pharmaceutically acceptable support, while excluding any step of exposing the nanoparticle or nanoparticle aggregate to an electric field or any other external activation source and excluding use of the nanoparticles as carrier of therapeutic compound(s) or drug(s).
Restricting nanoparticle material classes by conductor, semiconductor, and insulator thresholds
Selecting nanoparticle or nanoparticle aggregate material from a conductor material including metals with a standard reduction potential E0 above 0.2 and/or an organic material with contiguous sp2 hybridized carbon centers; a semiconductor material with band gap Eg below 3.0 eV; a mixed-metal oxide insulator material with dielectric constant εijk equal to or above 200; and an insulator material with dielectric constant εijk equal to or below 100 selected from Al2O3, LaAlO3, La2O3, SiO2, SnO2, Ta2O5, ReO2, ZrO2, HfO2, Y2O3 and carbon diamond, with εijk measured between 20°C and 30°C and between 10^2 Hz up to the infrared frequency.
Imposing core-size and biocompatible coating surface-charge constraints
Requiring that the median largest core size of the nanoparticle or nanoparticle aggregate population is at least 30 nm when the material is a conductor material, a semiconductor material or an insulator material with a dielectric constant εijk equal to or above 200; and that the core is coated with a biocompatible coating providing a neutral or a negative surface charge when measured in water having electrolyte concentration between 0.001 and 0.2 M, nanoparticle concentration between 0.01 and 10 g/L, and pH between 6 and 8.
Providing a composition or kit with at least two distinct constrained nanoparticles or nanoparticle aggregates
A composition or kit comprising at least two distinct nanoparticles or nanoparticle aggregates, each having material selected from the same conductor, semiconductor, and insulator classes with the same εijk measurement conditions, and each having median largest core size of at least 30 nm for the conductor, semiconductor, and εijk equal to or above 200 insulator materials, and a biocompatible coating providing a neutral or negative surface charge under the specified aqueous electrolyte, nanoparticle concentration, and pH conditions, while not using the nanoparticles or nanoparticle aggregates as carrier of therapeutic compound(s) or drug(s).
Across the independent claims, the inventive scope centers on administering or packaging multiple nanoparticles with constrained conductor, semiconductor, and insulator material classes, specified dielectric or electronic property ranges, a minimum core size for defined classes, and biocompatible coatings that yield neutral or negative surface charge under defined aqueous conditions, while excluding therapeutic-compound loading and any electric-field or external activation exposure.
Stated Advantages
Enhancing brain performance.
Preventing or treating pathological stress.
Enhancing physical performance, learning, memorizing, sense perception, attention and/or decision making of a subject.
Documented Applications
Enhancing brain performance in a subject.
Preventing or treating pathological stress in a subject.
Enhancing physical performance and cognitive functions including learning, memorizing, sense perception, attention and/or decision making.
Interested in licensing this patent?